AstraZeneca, Breast Cancer
AstraZeneca PLC AZN shares rallied 2.39% to £110.52 Tuesday, on what proved to be an all-around great trading session for the ...
DXd, significantly improved median progression-free survival in a Phase III study but failed to do so for overall survival.
AstraZeneca (AZN) has overhauled its local management in China in a bid to move on from recent scandals and revive sales after the arrest of ...
Shares of AstraZeneca PLC AZN slid 1.32% to £107.94 Monday, on what proved to be an all-around great trading session for the ...
Analysts predict sales of Dato-DXd could hit $5.9 billion in 2030, but the antibody-drug conjugate faced a series of setbacks ...
Goldman Sachs analyst Rajan Sharma maintained a Buy rating on AstraZeneca (AZN – Research Report) today and set a price target of £155.58. The ...
From accelerating drug development and clinical trials to supercharging collaboration, machine learning-enhanced healthcare ...
Trinasolar, a global leader in smart PV and energy storage, has partnered with Smart Commercial Solar to deliver an advanced ...
AstraZeneca has overhauled its local management in China, replacing Michael Lai with Alex Lin as the country's general ...
President Trump rescinded an executive order that prompted the creation of three Medicare drug-pricing experiments ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback